biology-news-1/american-chemical-societys-weekly-presspac----sept--19--2007-525-8/www.chemistry.org/2006annualreport.html

Breaking Biology Technology:MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2 MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3 MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4 BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes 2 BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes 3 Waters Ships First Units of SYNAPT G2 Mass Spectrometer 2 Oxford BioTherapeutics Appoints Michael Moore as Chairman 2 Oxford BioTherapeutics Appoints Michael Moore as Chairman 3 Oxford BioTherapeutics Appoints Michael Moore as Chairman 4

[0] MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products [0] BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes [0] Waters Ships First Units of SYNAPT G2 Mass Spectrometer [0] Oxford BioTherapeutics Appoints Michael Moore as Chairman

Breaking Medicine Technology:Within3 Expands into Mobile Applications 2 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6 Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2 Tim McGraw and Faith Hill Join Senior Military for Country United 3A Advancing Medicine From the Frontlines to the Homefront 47536 1 Tim McGraw and Faith Hill Join Senior Military for Country United 3A Advancing Medicine From the Frontlines to the Homefront 47536 2 Tim McGraw and Faith Hill Join Senior Military for Country United 3A Advancing Medicine From the Frontlines to the Homefront 47536 3 New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography 47533 1 New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography 47533 2 New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography 47533 3 Viewers Beware Report by Watchdog Group Exposes Conservative Group Behind Anti Healthcare Ads Running in Montana 47530 1 Viewers Beware Report by Watchdog Group Exposes Conservative Group Behind Anti Healthcare Ads Running in Montana 47530 2

[0] Within3 Expands into Mobile Applications [0] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer [0] Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program